SG11201505941PA - Cytoplasmic expression of fab proteins - Google Patents
Cytoplasmic expression of fab proteinsInfo
- Publication number
- SG11201505941PA SG11201505941PA SG11201505941PA SG11201505941PA SG11201505941PA SG 11201505941P A SG11201505941P A SG 11201505941PA SG 11201505941P A SG11201505941P A SG 11201505941PA SG 11201505941P A SG11201505941P A SG 11201505941PA SG 11201505941P A SG11201505941P A SG 11201505941PA
- Authority
- SG
- Singapore
- Prior art keywords
- cytoplasmic expression
- fab proteins
- fab
- proteins
- cytoplasmic
- Prior art date
Links
- 230000001086 cytosolic effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
- C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013900572A AU2013900572A0 (en) | 2013-02-20 | Cytoplasmic expression of fab proteins | |
| PCT/IB2014/059107 WO2014128628A1 (en) | 2013-02-20 | 2014-02-20 | Cytoplasmic expression of fab proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201505941PA true SG11201505941PA (en) | 2015-09-29 |
Family
ID=51390573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201505941PA SG11201505941PA (en) | 2013-02-20 | 2014-02-20 | Cytoplasmic expression of fab proteins |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160002317A1 (en) |
| EP (1) | EP2959041A4 (en) |
| AU (1) | AU2014220306A1 (en) |
| CA (1) | CA2901385A1 (en) |
| SG (1) | SG11201505941PA (en) |
| WO (1) | WO2014128628A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6244301B2 (en) | 2011-08-18 | 2017-12-06 | アフィニティ バイオサイエンス ピーティーワイ リミテッド | Soluble polypeptide |
| GB2616707B (en) * | 2023-01-10 | 2024-04-17 | Rxbiologics Ltd | Antibody discovery methods |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010028791A1 (en) * | 2008-09-10 | 2010-03-18 | Philochem Ag | Display library for antibody selection |
| US8716196B2 (en) * | 2009-05-20 | 2014-05-06 | Novimmune S.A. | Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants |
| SG175407A1 (en) * | 2009-05-29 | 2011-11-28 | Morphosys Ag | A collection and methods for its use |
| WO2011075761A1 (en) * | 2009-12-23 | 2011-06-30 | Affinity Biosciences Pty Ltd | Protein display |
| CA2840650C (en) * | 2011-06-29 | 2019-08-20 | Affinity Biosciences Pty Ltd | Method of protein display |
| JP6244301B2 (en) * | 2011-08-18 | 2017-12-06 | アフィニティ バイオサイエンス ピーティーワイ リミテッド | Soluble polypeptide |
-
2014
- 2014-02-20 WO PCT/IB2014/059107 patent/WO2014128628A1/en not_active Ceased
- 2014-02-20 EP EP14753894.6A patent/EP2959041A4/en not_active Withdrawn
- 2014-02-20 SG SG11201505941PA patent/SG11201505941PA/en unknown
- 2014-02-20 AU AU2014220306A patent/AU2014220306A1/en not_active Abandoned
- 2014-02-20 US US14/768,678 patent/US20160002317A1/en not_active Abandoned
- 2014-02-20 CA CA2901385A patent/CA2901385A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160002317A1 (en) | 2016-01-07 |
| CA2901385A1 (en) | 2014-08-28 |
| AU2014220306A1 (en) | 2015-08-27 |
| EP2959041A4 (en) | 2016-08-24 |
| EP2959041A1 (en) | 2015-12-30 |
| WO2014128628A1 (en) | 2014-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL320900A (en) | Heterodimeric proteins | |
| IL269528A (en) | Anti-fcrh5 antibodies | |
| SG10201801428RA (en) | Method for increasing expression of rna-encoded proteins | |
| GB201322583D0 (en) | Antibodies | |
| IL244043A0 (en) | Antibodies | |
| IL244588A0 (en) | Fusion protein | |
| GB201308658D0 (en) | Antibodies | |
| GB201315486D0 (en) | Antibodies | |
| IL240474A0 (en) | Cartilage-binding fusion proteins | |
| IL245488A0 (en) | Anti-ccl17 antibodies | |
| SI3016977T1 (en) | Human anti-il-32 antibodies | |
| GB201308057D0 (en) | Protein | |
| SG11201505941PA (en) | Cytoplasmic expression of fab proteins | |
| GB201401955D0 (en) | Protein | |
| EP2978770A4 (en) | Refolding of proteins | |
| GB201314945D0 (en) | Protein crystals | |
| AU2013900572A0 (en) | Cytoplasmic expression of fab proteins | |
| GB201302031D0 (en) | Protein | |
| GB201302030D0 (en) | Protein | |
| GB201318283D0 (en) | Antibodies |